If not now, when? Prescription of evidence-based medical therapy prior to hospital discharge increases utilization at 6 months in patients with symptomatic peripheral artery disease

We evaluated the impact of the prescription of evidence-based medical therapy (EBMT) including aspirin (ASA), beta-blockers (BB), ACE-inhibitors or angiotensin receptor blockade (ACE/ARB), and statins prior to discharge after peripheral vascular intervention (PVI) on long-term medication utilization...

Full description

Saved in:
Bibliographic Details
Published in:Vascular medicine (London, England) England), 2015-12, Vol.20 (6), p.544-550
Main Authors: Renard, Brian M, Seth, Milan, Share, David, Aronow, Herb D, Laveroni, Eugene W, De Gregorio, Michele, Hans, Sachinder S, Henke, Peter K, Gurm, Hitinder S, Grossman, P Michael
Format: Article
Language:English
Subjects:
Cardiovascular Agents - therapeutic use
Drug Prescriptions
Drug Utilization Review
Evidence-Based Medicine - standards
Female
Humans
Linear Models
Logistic Models
Male
Multivariate Analysis
Odds Ratio
Patient Discharge
Peripheral Arterial Disease - diagnosis
Peripheral Arterial Disease - drug therapy
Peripheral Arterial Disease - physiopathology
Practice Patterns, Physicians' - standards
Quality Improvement
Quality Indicators, Health Care
Registries
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the impact of the prescription of evidence-based medical therapy (EBMT) including aspirin (ASA), beta-blockers (BB), ACE-inhibitors or angiotensin receptor blockade (ACE/ARB), and statins prior to discharge after peripheral vascular intervention (PVI) on long-term medication utilization in a large multi-specialty, multicenter quality improvement collaborative. Among patients undergoing coronary revascularization, use of the component medications of EBMT at hospital discharge is a major predictor of long-term utilization. Predictors of EBMT use after PVI are largely unknown. A total of 10,169 patients undergoing PVI between 1 January 2008 and 31 December 2011 were included. Post-PVI discharge and 6-month medication utilization in patients without contra-indications to ASA, BB, ACE/ARB, and statins were compared. ASA was prescribed at discharge to 9345 (92%) patients, BB to 7012 (69%), ACE/ARB to 6424 (63%), and statins to 8342 (82%), and all four component drugs of EBMT in 3953 (39%). Compared with patients not discharged on the appropriate medications, post-procedural use was associated (all p
ISSN:1358-863X
1477-0377
DOI:10.1177/1358863X15599249